This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
Age 18-65 inclusive, at the time of signing the informed consent.
Chronic AD for at least 1 year based on clinically confirmed diagnosis of active AD, according to Hanfin and Rajka criteria.
Investigator global assessment (IGA) score of ≥ 3 (on a scale of 0 to 4, in which three is moderate and four is severe) at Screening and Baseline.
AD involvement of ≥ 10% body surface area (BSA) at Screening and Baseline.
History or other evidence of severe illness or any other conditions such as psychiatric illness, severe depression or previous history of suicidal attempt in past 10 years that would render the participant, in the opinion of the Investigator, unsuitable for the study.
Active, chronic or acute infection requiring systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the Baseline.
Participant has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of AD or would interfere with the study assessments based on the Investigator's judgement.
Participant has history of significant flares of AD within 4 weeks prior to screening, in the opinion of the investigator.
Apollo Therapeutics Ltd
Lead sponsor